AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Q-Linea

Board/Management Information Apr 28, 2025

3100_rns_2025-04-28_8182a51d-c6b8-4c9f-ba45-42e6cc63c55a.pdf

Board/Management Information

Open in Viewer

Opens in native device viewer

Q-linea announces changes in executive leadership team

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA) today announces that Natalie Brown has been appointed Director Global Marketing and will join the Executive Management Group as of July 1, 2025. The company also announces the departure of Karl Sköld, Director System & Support.

Natalie will lead the global marketing activities and work closely with the commercial teams in the US and in EMEA. Natalie will continue to be based in the US.

"Natalie brings a wealth of experience to the Q-linea team, and her expanded role will elevate the conversation within the Executive Management Group", says Q-linea CEO Stuart Gander.

Director System & Support Karl Sköld will leave Q-linea mid-June after transitioning responsibilities within the executive team. "I would like to extend my gratitude for the leadership and expertise provided by Karl who has supported our journey for seven years across a variety of domains and leadership roles", says Stuart.

Q-linea is a leader in rapid antimicrobial susceptibility testing (rAST). "I am excited to build on the strong foundation established by the commercial teams in the US and in EMEA and look forward to accelerating our global growth trajectory", says Natalie Brown.

For more information, please contact:

Stuart Gander, President & CEO, Q-linea [email protected] +1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB [email protected] +46 (0) 70-600 15 20

About Q-linea

Q-linea's rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.

Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.

ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

Attachments

Q-linea announces changes in executive leadership team

Talk to a Data Expert

Have a question? We'll get back to you promptly.